Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.59 |
| ▸ | ITGAV | P06756 | 19/20 | 0.59 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.55 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.55 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.53 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28747079 | 0.77 | ITGB1 (0.53) | ITGB3ITGAVITGB6ITGB1ITGB5 | |
| SCHEMBL16607505 | 0.74 | ALDH1A1 (0.53) | ITGB3ITGAVITGB6ITGB1ITGB5 | |
| SCHEMBL6094121 | 0.74 | ITGB6 (0.48) | ITGB3ITGAVITGB6ITGB1ITGB5 | |
| SCHEMBL6098574 | 0.74 | ITGB3 (0.47) | ITGB3ITGAVITGB6ITGB1ITGB5 | |
| SCHEMBL24743258 | 0.73 | HDAC3 (0.60) | ITGB3ITGAVITGB6ITGB1ITGB5 | |
| SCHEMBL19892578 | 0.72 | HPGD (0.69) | ITGB1ITGA5 | |
| SCHEMBL7264806 | 0.72 | ITGB3 (0.94) | ITGB3ITGAVITGB6ITGB1ITGB5 | |
| SCHEMBL5846620 | 0.72 | ITGB3 (0.69) | ITGB3ITGAVITGB6ITGB1ITGB5 | |
| SCHEMBL6097098 | 0.72 | ITGB3 (0.46) | ITGB3ITGAVITGB6ITGB1ITGB5 | |
| SCHEMBL5691034 | 0.72 | EEF2K (0.48) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1061921-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-03-30 | — | — | EP | claimed |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| CN-1299282-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 2001-06-13 | — | — | CN | claimed |
| EP-1061921-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-27 | — | — | EP | claimed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | claimed |
| EP-1061921-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| CN-1299282-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 2001-06-13 | — | — | CN | disclosed |
| EP-1061921-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147334-A1 | Vitronectin Receptor Antagonists | ADGRF1, FN1, CALCR | ITGB3 82/4885ITGAV 146/4885ITGB6 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.